D. Boral Capital initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $15 price target Coya believes that through exactly the right combination, concentration, and dose of IL-1 and CTLA4, the company can ameliorate the deleterious out of a balanced immune system that contributes to the rapid decline seen in amyotrophic lateral sclerosis patients, the analyst tells investors in a research note. The firm says a small proof-of-concept study demonstrated the viability of the approach. Coya developed a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain, it adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics files to sell 1.38M shares of common stock for holders
- Coya: COYA 301 – GLP-1 agonists combo synergistic in inflamation amelioration
- Coya Therapeutics Reports Q3 2024 Highlights and Progress
- Coya Therapeutics Advances Pipeline for Neurodegenerative Diseases
- Coya Therapeutics reports Q3 EPS (26c), consensus (41c)